Zydus LifesciencesBOM:532321 -0.81%92 EBITDA Margin % is 30.82% as of Mar. 2026, which is 24% above its 10-year median of 24.88. GuruFocus rates BOM:532321 with a GF Score™ of 92/100 and a GF Value™ of ₹1,151.95 (Fairly Valued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Zydus Lifesciences ranks better than 88.6% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zydus Lifesciences's EBITDA for the
three
months ended in Mar. 2026 was ₹22,911 Mil. Zydus Lifesciences's Revenue for the
three
months ended in Mar. 2026 was ₹74,344 Mil. Therefore, Zydus Lifesciences's EBITDA margin for the quarter that ended in Mar. 2026 was 30.82%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zydus Lifesciences EBITDA Margin % Related Terms
Zydus Lifesciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zydus Lifesciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532321 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zydus Lifesciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zydus Lifesciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zydus Lifesciences (BOM:532321) has a EBITDA Margin % of 30.82% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zydus Lifesciences and its competitors. This is 24% above median its historical median of 24.88. Over the past decade, Zydus Lifesciences' EBITDA Margin % has ranged from 18.21 to 31.69. According to the industry distribution chart, Zydus Lifesciences ranks #109 out of 956 companies in the Drug Manufacturers industry, placing it in the top 11.4%.
Is Zydus Lifesciences' EBITDA Margin % too high?
Zydus Lifesciences' current EBITDA Margin % of 30.82% is 24% above median its 10-year median of 24.88. Over the past 10 years, this metric has ranged from a low of 18.21 to a high of 31.69. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Zydus Lifesciences' value of 30.82% is 146.3% above this industry median. Based on the distribution chart, Zydus Lifesciences ranks #109 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zydus Lifesciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zydus Lifesciences ranks #109 out of 956 companies for EBITDA Margin %. This places Zydus Lifesciences in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Zydus Lifesciences' value of 30.82% is 146.3% above this benchmark. Historically, Zydus Lifesciences' own EBITDA Margin % has ranged from 18.21 to 31.69 over the past decade. While the company's 10-year median is 24.88 vs. the industry median of 12.52, Zydus Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zydus Lifesciences's current EBITDA Margin % of 30.82% is 146.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zydus Lifesciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zydus Lifesciences's current EBITDA Margin % is 30.82%, which is 24% above median its own 10-year median of 24.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (BOM:532321) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,151.95, compared to a current price of ₹1,150.50 — trading 0.1% below its estimated fair value. The current EBITDA Margin % is 30.82%, which is 24% above median its 10-year median of 24.88 and 146.3% above the Drug Manufacturers industry median of 12.52. Zydus Lifesciences' overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zydus Lifesciences (BOM:532321), the current EBITDA Margin % is 30.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zydus Lifesciences (BOM:532321) Overvalued in 2026?
Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued.
The current stock price of ₹1,150.50 is trading 0.1% below its estimated GF Value™ of ₹1,151.95.
GuruFocus considers Zydus Lifesciences to be Fairly Valued.
Key valuation signals for BOM:532321:
EBITDA Margin %: 30.82% (24% above median its 10-year median of 24.88)
GF Value™: ₹1,151.95 vs. price of ₹1,150.50 (0.1% below fair value)
Industry Position: 146.3% above the Drug Manufacturers median (#109 of 956)
No single metric tells the full story. See the BOM:532321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
92GF Score
Get the complete analysis for BOM:532321
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532321 has been successfully added to your 
